|
DE19821625C1
(de)
*
|
1998-05-15 |
2000-01-05 |
Merck Patent Gmbh |
Pharmazeutische Zubereitung
|
|
DE19830246A1
(de)
*
|
1998-07-07 |
2000-01-13 |
Merck Patent Gmbh |
Pharmazeutische Zubereitung
|
|
JP2002540073A
(ja)
*
|
1999-03-10 |
2002-11-26 |
ロータス バイオケミカル コーポレイション |
化学化合物の保護および放出のためのタンパク質コンホメーションの使用
|
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
BR0013719A
(pt)
*
|
1999-09-02 |
2002-07-23 |
Nostrum Pharmaceuticals Inc |
Dosagem oral de liberaçâo controlada, apropriada para administração oral
|
|
US6627660B1
(en)
|
1999-11-16 |
2003-09-30 |
New River Pharmaceuticals Inc. |
Stabilized thyroxine compounds
|
|
US9522217B2
(en)
|
2000-03-15 |
2016-12-20 |
Orbusneich Medical, Inc. |
Medical device with coating for capturing genetically-altered cells and methods for using same
|
|
US20070141107A1
(en)
*
|
2000-03-15 |
2007-06-21 |
Orbusneich Medical, Inc. |
Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
|
|
US8088060B2
(en)
|
2000-03-15 |
2012-01-03 |
Orbusneich Medical, Inc. |
Progenitor endothelial cell capturing with a drug eluting implantable medical device
|
|
US6399101B1
(en)
|
2000-03-30 |
2002-06-04 |
Mova Pharmaceutical Corp. |
Stable thyroid hormone preparations and method of making same
|
|
CA2408796C
(en)
|
2000-05-24 |
2009-12-15 |
Otsuka Pharmaceutical Co., Ltd. |
Method of stabilizing preparation
|
|
EP1157682A1
(en)
*
|
2000-05-25 |
2001-11-28 |
Cilag AG |
Blister package for topiramate tablets
|
|
US6855333B1
(en)
|
2000-10-03 |
2005-02-15 |
Mutual Pharmaceutical Co., Inc. |
Stabilization of solid thyroid drug formulations
|
|
US6979462B1
(en)
|
2000-10-03 |
2005-12-27 |
Mutual Pharmaceutical Co., Inc. |
Stabilization of solid drug formulations
|
|
US8394813B2
(en)
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
RS20100015A
(sr)
|
2001-01-26 |
2010-12-31 |
Schering Corporation |
Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
|
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
PT1355644E
(pt)
|
2001-01-26 |
2006-11-30 |
Schering Corp |
Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
|
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
|
JP2004525109A
(ja)
*
|
2001-02-15 |
2004-08-19 |
キング・ファーマシューティカルズ・インコーポレイティッド |
安定化された甲状腺ホルモン医薬組成物、及びその製法
|
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
|
GB0113841D0
(en)
*
|
2001-06-07 |
2001-08-01 |
Boots Co Plc |
Therapeutic agents
|
|
ITMI20011401A1
(it)
|
2001-07-02 |
2003-01-02 |
Altergon Sa |
Formulazioni farmaceutiche per ormoni tiroidei
|
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
|
US20030194436A1
(en)
*
|
2001-08-10 |
2003-10-16 |
Franz Andrew G. |
Immediate release pharmaceutical compositions
|
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
|
US20030199585A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz G Andrew |
Levothyroxine compositions and methods
|
|
US20030198671A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique plasma AUC properties
|
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
|
AU2002332507A1
(en)
*
|
2001-08-10 |
2003-02-24 |
King Pharmaceuticals, Inc. |
Levothyroxine compositions and methods
|
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
|
WO2003028624A2
(en)
*
|
2001-08-14 |
2003-04-10 |
King Pharmaceuticals, Inc |
Levothyroxine compositions and methods
|
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
|
US20030194437A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Cmax properties
|
|
US7101569B2
(en)
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
|
US20060014697A1
(en)
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
|
US7169752B2
(en)
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
EP1429756B1
(en)
|
2001-09-21 |
2006-11-22 |
Schering Corporation |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
|
US20040043066A1
(en)
*
|
2001-10-29 |
2004-03-04 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
|
US6645526B2
(en)
*
|
2001-11-13 |
2003-11-11 |
Mylan Pharmaceuticals, Inc. |
Storage stable thyroxine active drug formulations and methods for their production
|
|
US20030099699A1
(en)
*
|
2001-11-13 |
2003-05-29 |
Hanshew Dwight D. |
Storage stable thyroxine active drug formulations and methods for their production
|
|
AU2003207467A1
(en)
*
|
2002-01-07 |
2003-07-24 |
Abbott Gmbh And Co. Kg |
Crystallization of amino acids using ultrasonic agitation
|
|
AU2003241537A1
(en)
*
|
2002-05-23 |
2003-12-12 |
Andrx Corporation |
Biguanide formulations
|
|
WO2004014318A2
(en)
*
|
2002-08-10 |
2004-02-19 |
King Pharmaceuticals, Inc. |
Levothyroxine compositions and methods
|
|
WO2004041208A2
(en)
*
|
2002-11-05 |
2004-05-21 |
New River Pharmaceuticals Inc. |
Controlled absorption of mixed thyroyd hormone formulations
|
|
JP2006508188A
(ja)
|
2002-11-06 |
2006-03-09 |
シェーリング コーポレイション |
脱髄の処置のためのコレステロール吸収インヒビター
|
|
ITMI20022394A1
(it)
|
2002-11-13 |
2004-05-14 |
Bracco Spa |
Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
|
|
ITMI20110713A1
(it)
|
2011-04-29 |
2012-10-30 |
Bracco Imaging Spa |
Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
DE602004016123D1
(de)
|
2003-03-07 |
2008-10-09 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
|
CN1756755A
(zh)
*
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
|
CN1756756A
(zh)
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
|
US8293272B2
(en)
*
|
2003-05-02 |
2012-10-23 |
Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. |
Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
|
|
WO2004096177A1
(de)
*
|
2003-05-02 |
2004-11-11 |
Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. |
Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
|
|
GB0316206D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Glaxo Group Ltd |
Pharmaceutical formulation
|
|
US20060008512A1
(en)
*
|
2004-07-07 |
2006-01-12 |
Hooge Danny M |
Composition and methods for improved animal performance
|
|
US8318712B2
(en)
*
|
2006-01-06 |
2012-11-27 |
Intervet International B.V. |
Concentrated liquid thyroid hormone composition
|
|
US7858663B1
(en)
|
2007-10-31 |
2010-12-28 |
Pisgah Laboratories, Inc. |
Physical and chemical properties of thyroid hormone organic acid addition salts
|
|
GB2457710A
(en)
*
|
2008-02-25 |
2009-08-26 |
Andrew Nicolaou |
Thyroxine and its use in weight loss and obesity treatment
|
|
IT1395454B1
(it)
*
|
2009-03-24 |
2012-09-21 |
Altergon Sa |
Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
|
|
EP2248518B1
(en)
|
2009-04-17 |
2013-01-16 |
Merz Pharma GmbH & Co. KGaA |
Formulation for stabilizing proteins, peptides or mixtures thereof.
|
|
EP2461804A4
(en)
*
|
2009-08-04 |
2013-10-02 |
Haren Treasurer |
IMPROVED USE WITH THYROID HORMONE
|
|
AU2011316111B2
(en)
|
2010-10-12 |
2015-05-28 |
Merz Pharma Gmbh & Co. Kgaa |
Formulation suitable for stabilizing proteins, which is free of mammalian excipients
|
|
AR083417A1
(es)
|
2010-10-14 |
2013-02-21 |
Novartis Ag |
Composiciones farmaceuticas que contienen un dgat1 inhibidor
|
|
MX348467B
(es)
*
|
2011-04-08 |
2017-06-13 |
Bracco Imaging Spa |
Proceso para la preparación de un derivado sulfatado de 3,5-diiodo-o-[3-iodofenil]-l-tirosina.
|
|
EP2750664A1
(en)
|
2011-08-30 |
2014-07-09 |
Fresenius Kabi USA, LLC |
Levothyroxine formulations
|
|
US8779000B1
(en)
*
|
2013-07-20 |
2014-07-15 |
Nilesh Parikh |
Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
|
|
EP2932963A1
(en)
*
|
2014-04-16 |
2015-10-21 |
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. |
Stable pharmaceutical dosage forms comprising Levothyroxine sodium
|
|
US11154498B2
(en)
|
2015-07-22 |
2021-10-26 |
Leiutis Pharmaceuticals Pvt. Ltd. |
Stabilized liquid formulation of levothyroxine
|
|
WO2017077476A1
(en)
|
2015-11-04 |
2017-05-11 |
Leiutis Pharmaceuticals Pvt Ltd |
Novel levothyroxine formulations for oral use
|
|
NL2017110B1
(en)
*
|
2016-07-05 |
2018-01-12 |
Emp Levo Gmbh |
Methods for the preparation of a levothyroxine solution
|
|
US10231931B1
(en)
|
2018-03-23 |
2019-03-19 |
Genus Lifesciences Inc. |
Thyroid hormone oral dosage forms and methods of using the same
|
|
TW202227047A
(zh)
*
|
2020-10-09 |
2022-07-16 |
日商Ａｓｋａ製藥股份有限公司 |
甲狀腺荷爾蒙的製劑化方法
|
|
WO2023088976A1
(en)
|
2021-11-16 |
2023-05-25 |
Tap Pharmaceuticals, Ag |
Orodispersible levothyroxine compositions
|